menu
    • menu
    [{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Ponsegromab","moa":"GDF15","graph1":"Nutrition and Weight Loss","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"CatalYm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Visugromab","moa":"GDF15","graph1":"Nutrition and Weight Loss","graph2":"Phase II\/ Phase III","graph3":"CatalYm","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CatalYm \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"CatalYm \/ Undisclosed"},{"orgOrder":0,"company":"Centre For International Health","sponsor":"Tribhuvan University, Nepal | NORCE Norwegian Research Centre AS","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"NORWAY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2014","type":"Inapplicable","leadProduct":"Vitamin B12","moa":"Methionine synthase; Methylmalonyl-CoA mutase, mitochondrial; Methionine synthase reductase; Methylmalonic aciduria type A protein, mitochondrial; Cyanocobalamin reductase \/ alkylcobalamin dealkylase; Methylenetetrahydrofolate reductase (NADPH)","graph1":"Nutrition and Weight Loss","graph2":"Phase II\/ Phase III","graph3":"Centre For International Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Paste","sponsorNew":"Centre For International Health \/ Tribhuvan University, Nepal | NORCE Norwegian Research Centre AS","highestDevelopmentStatusID":"9","companyTruncated":"Centre For International Health \/ Tribhuvan University, Nepal | NORCE Norwegian Research Centre AS"},{"orgOrder":0,"company":"Roquette Freres","sponsor":"Sprim Advanced Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Dietary Supplement","year":"2010","type":"Inapplicable","leadProduct":"Maltodextrin","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II\/ Phase III","graph3":"Roquette Freres","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Roquette Freres \/ Sprim Advanced Life Sciences","highestDevelopmentStatusID":"9","companyTruncated":"Roquette Freres \/ Sprim Advanced Life Sciences"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2015","type":"Inapplicable","leadProduct":"Nutritional Supplement","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II\/ Phase III","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Abbott Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Nutritional Supplement","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II\/ Phase III","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Abbott Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Catalysis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Dietary Supplement","year":"2014","type":"Inapplicable","leadProduct":"Obex","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II\/ Phase III","graph3":"Catalysis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Catalysis \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Catalysis \/ Undisclosed"},{"orgOrder":0,"company":"International Centre for Diarrhoeal Disease Research, Bangladesh","sponsor":"UNICEF | Nutriset","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"BANGLADESH","productType":"Dietary Supplement","year":"2013","type":"Inapplicable","leadProduct":"Rutf-1","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II\/ Phase III","graph3":"International Centre for Diarrhoeal Disease Research, Bangladesh","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Centre for Diarrhoeal Disease Research, Bangladesh \/ UNICEF | Nutriset","highestDevelopmentStatusID":"9","companyTruncated":"International Centre for Diarrhoeal Disease Research, Bangladesh \/ UNICEF | Nutriset"},{"orgOrder":0,"company":"Faes Farma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SPAIN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Calcifediol","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II\/ Phase III","graph3":"Faes Farma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Faes Farma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Faes Farma \/ Undisclosed"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CatalYm

                            Germany arrow
                            OTS 2025
                            Not Confirmed

                            CatalYm

                            Germany arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Visugromab

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Visugromab in Cachexia International Trial

                            Details : Visugromab is a Antibody drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Cancer Cachexia.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            August 08, 2025

                            Lead Product(s) : Visugromab

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Pfizer Inc

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Pfizer Inc

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ponsegromab

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ponsegromab Safety and Effects In Advanced Pancreatic Cancer with Cachexia

                            Details : Ponsegromab is a Antibody drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Cachexia.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            May 25, 2025

                            Lead Product(s) : Ponsegromab

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Protara Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Protara Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Choline Chloride

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Lon...

                            Details : Choline Chloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Choline Deficiency.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 04, 2025

                            Lead Product(s) : Choline Chloride

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Faes Farma

                            Spain arrow
                            OTS 2025
                            Not Confirmed

                            Faes Farma

                            Spain arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Calcifediol

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Calcifediol vs Placebo in Subjects With Vitamin D Deficiency

                            Details : Calcifediol is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Vitamin D Deficiency.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            February 03, 2021

                            Lead Product(s) : Calcifediol

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Rhythm Pharmaceuticals

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Rhythm Pharmaceuticals

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Setmelanotide Acetate

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Long Term Extension Trial of Setmelanotide

                            Details : Setmelanotide is a Protein drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Obesity-associated with Leptin-melanocortin Pathway Defects.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            August 29, 2018

                            Lead Product(s) : Setmelanotide Acetate

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Abbott Laboratories

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Abbott Laboratories

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nutritional Supplement

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Oral Nutritional Supplementation in Picky Eating Children

                            Details : Nutritional Supplement is a Dietary Supplement drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Malnutrition.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            August 14, 2015

                            Lead Product(s) : Nutritional Supplement

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Centre For International Health

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Centre For International Health

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vitamin B12

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II/ Phase III

                            Sponsor : Tribhuvan University, Nepal | NORCE Norwegian Research Centre AS

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vitamin B12, Neurodevelopment and Growth in Nepal

                            Details : Vitamin B12 is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Avitaminosis.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            October 23, 2014

                            Lead Product(s) : Vitamin B12

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Tribhuvan University, Nepal | NORCE Norwegian Research Centre AS

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Catalysis

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Catalysis

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Obex

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effects of Obex in Overweight and Obese Patients

                            Details : Obex is a Dietary Supplement drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Overweight.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            May 23, 2014

                            Lead Product(s) : Obex

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Catalysis

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Catalysis

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Obex

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Obex, a Nutritional Supplement, in Overweight and Obese Spanish Women

                            Details : Obex is a Dietary Supplement drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Obesity.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            September 04, 2013

                            Lead Product(s) : Obex

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            International Centre for Diarrhoeal Disease Research, Bangladesh

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            International Centre for Diarrhoeal Disease Research, Bangladesh

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rutf-1

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II/ Phase III

                            Sponsor : UNICEF | Nutriset

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Development and Field Testing of Ready-to-use-therapeutic Foods Made of Local Ingredients in Bangladesh for SA...

                            Details : Rutf-1 is a Dietary Supplement drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Malnutrition.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            June 28, 2013

                            Lead Product(s) : Rutf-1

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : UNICEF | Nutriset

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth